GENFIT 9-Months 2025 Revenue €39.2 Million; Says As of September 30, 2025, The Company's Cash And Cash Equivalents Amounted To €119.0 Million Compared With €107.5 Million As Of June 30, 2025, And €81.8 Million As Of December 31, 2024

Author: Benzinga Newsdesk | November 20, 2025 12:13pm

• Cash and cash equivalents totaled €119.0 million as of September 30, 2025
• €39.2 million in revenues for the nine months ended September 30, 2025, including the €26.5 million milestone payment following pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European markets

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its third quarter 2025 financial results1 and provided a corporate update.

Cash Position

As of September 30, 2025, the Company's cash and cash equivalents amounted to €119.0 million compared with €107.5 million as of June 30, 2025, and €81.8 million as of December 31, 2024.

We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the end of 2028, enabling the Company to further develop its pipeline focused on Acute on-Chronic Liver Failure (ACLF) and support general corporate purposes. This is based on current assumptions and programs and does not include exceptional events. This estimation assumes (i) our expectation to receive significant future commercial milestone revenue pursuant to the license agreement with Ipsen and Ipsen meeting its sales-based thresholds and (ii) drawing down all additional installments under the Royalty Financing agreement with HCRx.

In the first nine months of 2025, cash utilization is mainly the result of our research and development efforts in our pipeline focused on ACLF (notably VS-01, G1090N2, SRT-015, CLM-022, and VS-02 HE), as well as GNS561 in cholangiocarcinoma (CCA). Cash utilization was notably offset by a €26.5 million milestone payment received in July 2025 under the Licensing and Collaboration Agreement with Ipsen, following pricing and reimbursement approvals for Iqirvo® (elafibranor) in three major European markets3.

Revenue

Revenue4 for the first nine months of 2025 amounted to €39.2 million compared to €59.7 million for the same period in 2024.

Posted In: GNFT